Last reviewed 2026-04-23 · How we verify

GMI-1070

Inhibits the selectin family of adhesion molecules

Inhibits the selectin family of adhesion molecules Used for Acute myeloid leukemia.

At a glance

Mechanism of action

This mechanism of action is thought to inhibit the interaction between leukocytes and the endothelium, thereby reducing inflammation.

Approved indications

• Acute myeloid leukemia

Common side effects

• Thrombocytopenia
• Neutropenia

Key clinical trials

• Efficacy and Safety of Rivipansel (GMI-1070) in the Treatment of Vaso-Occlusive Crisis in Hospitalized Subjects With Sickle Cell Disease (PHASE3)
• Safety of Rivipansel (GMI-1070) in the Treatment of One or More Vaso-Occlusive Crises in Hospitalized Subjects With Sickle Cell Disease (PHASE3)
• A Study to Evaluate the Effect of IV Doses of Rivipansel in Subjects With Moderate Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function (PHASE1)
• A Study to Evaluate the Effect of IV Doses of Rivipansel on Subjects With Renal Impairment and in Healthy Subjects (PHASE1)
• A Study to Evaluate the Effect of Age on the Pharmacokinetics, Safety and Tolerability of IV Rivipansel. (PHASE1)
• Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Rivipansel With rHuPH20 in Healthy Subjects (PHASE1)
• A Study to Evaluate the Effect of IV Doses of GMI-1070 on Qtc Intervals in Healthy African-American Adult Subjects (PHASE1)
• Study of GMI-1070 for the Treatment of Sickle Cell Pain Crisis (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.